Do analysts rate PHIO or PPCB?

Phio Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 1,246.15%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Phio Pharmaceuticals is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, PHIO or PPCB?

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is PHIO or PPCB more profitable?

Phio Pharmaceuticals' return on equity of -77.34% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -77.34% -70.87% Propanc Biopharma N/A -151.28% -109.53%

Does the media favor PHIO or PPCB?

In the previous week, Propanc Biopharma had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 0.38 beat Propanc Biopharma's score of 0.30 indicating that Phio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PPCB or INAB?

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 233.33%. Given IN8bio's stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, PPCB or INAB?

IN8bio is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A IN8bio N/A N/A -$19.44M -$2.61 N/A

Is PPCB or INAB more profitable?

IN8bio's return on equity of -96.39% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% IN8bio N/A -96.39% -80.18%

Does the media favor PPCB or INAB?

In the previous week, Propanc Biopharma and Propanc Biopharma both had 3 articles in the media. IN8bio's average media sentiment score of 0.96 beat Propanc Biopharma's score of 0.30 indicating that IN8bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IN8bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PPCB or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer PPCB or BLRX?

In the previous week, Propanc Biopharma had 1 more articles in the media than BioLineRx. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.85 beat Propanc Biopharma's score of 0.30 indicating that BioLineRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioLineRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PPCB or AKTX?

Akari Therapeutics has a consensus target price of $32.33, indicating a potential upside of 271.65%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akari Therapeutics is more favorable than Propanc Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akari Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation and earnings, PPCB or AKTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A Akari Therapeutics N/A N/A -$17.30M N/A N/A

Is PPCB or AKTX more profitable?

Akari Therapeutics' return on equity of -123.29% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Propanc Biopharma N/A -151.28% -109.53% Akari Therapeutics N/A -123.29% -63.01%

Does the media refer more to PPCB or AKTX?

In the previous week, Akari Therapeutics had 3 more articles in the media than Propanc Biopharma. MarketBeat recorded 6 mentions for Akari Therapeutics and 3 mentions for Propanc Biopharma. Akari Therapeutics' average media sentiment score of 0.77 beat Propanc Biopharma's score of 0.30 indicating that Akari Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akari Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend XCUR or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, XCUR or PPCB?

Exicure is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exicure N/A N/A -$4.95M -$1.55 N/A Propanc Biopharma N/A N/A -$58.92M -$24.25 N/A

Is XCUR or PPCB more profitable?

Propanc Biopharma's return on equity of -151.28% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% Propanc Biopharma N/A -151.28% -109.53%

Propanc Biopharma (PPCB) Competitors

$1.37 -0.08 (-5.52%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.38 +0.01 (+1.02%)

As of 07/24/2026 07:32 PM Eastern

Compare

PPCB vs. PHIO, INAB, BLRX, AKTX, and XCUR

Should you buy Propanc Biopharma stock or one of its competitors? MarketBeat compares Propanc Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Propanc Biopharma include Phio Pharmaceuticals (PHIO), IN8bio (INAB), BioLineRx (BLRX), Akari Therapeutics (AKTX), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry.

How does Propanc Biopharma compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Phio Pharmaceuticals has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.49, indicating that its stock price is 249% more volatile than the broader market.

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

Phio Pharmaceuticals presently has a consensus price target of $14.00, indicating a potential upside of 1,246.15%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Phio Pharmaceuticals is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Propanc Biopharma had 1 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for Phio Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 0.38 beat Propanc Biopharma's score of 0.30 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 0.9% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Phio Pharmaceuticals' return on equity of -77.34% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Propanc Biopharma	N/A	-151.28%	-109.53%

Summary

Phio Pharmaceuticals beats Propanc Biopharma on 9 of the 13 factors compared between the two stocks.

How does Propanc Biopharma compare to IN8bio?

Propanc Biopharma (NASDAQ:PPCB) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

IN8bio's return on equity of -96.39% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
IN8bio	N/A	-96.39%	-80.18%

Propanc Biopharma has a beta of 3.49, meaning that its share price is 249% more volatile than the broader market. Comparatively, IN8bio has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

92.1% of IN8bio shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by company insiders. Comparatively, 14.5% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

IN8bio is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A

IN8bio has a consensus price target of $4.00, suggesting a potential upside of 233.33%. Given IN8bio's stronger consensus rating and higher possible upside, analysts clearly believe IN8bio is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Propanc Biopharma and Propanc Biopharma both had 3 articles in the media. IN8bio's average media sentiment score of 0.96 beat Propanc Biopharma's score of 0.30 indicating that IN8bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IN8bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IN8bio beats Propanc Biopharma on 9 of the 12 factors compared between the two stocks.

How does Propanc Biopharma compare to BioLineRx?

Propanc Biopharma (NASDAQ:PPCB) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

1.6% of BioLineRx shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Propanc Biopharma has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
BioLineRx	-563.70%	-37.73%	-19.42%

Propanc Biopharma has a beta of 3.49, indicating that its share price is 249% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

In the previous week, Propanc Biopharma had 1 more articles in the media than BioLineRx. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.85 beat Propanc Biopharma's score of 0.30 indicating that BioLineRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLineRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLineRx has higher revenue and earnings than Propanc Biopharma. BioLineRx is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
BioLineRx	$1.40M	8.79	-$1.17M	-$1.92	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioLineRx beats Propanc Biopharma on 7 of the 12 factors compared between the two stocks.

How does Propanc Biopharma compare to Akari Therapeutics?

Propanc Biopharma (NASDAQ:PPCB) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Propanc Biopharma has a beta of 3.49, meaning that its share price is 249% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

Akari Therapeutics has a consensus target price of $32.33, indicating a potential upside of 271.65%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akari Therapeutics is more favorable than Propanc Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Akari Therapeutics' return on equity of -123.29% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Akari Therapeutics	N/A	-123.29%	-63.01%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A

In the previous week, Akari Therapeutics had 3 more articles in the media than Propanc Biopharma. MarketBeat recorded 6 mentions for Akari Therapeutics and 3 mentions for Propanc Biopharma. Akari Therapeutics' average media sentiment score of 0.77 beat Propanc Biopharma's score of 0.30 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akari Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

5.1% of Akari Therapeutics shares are owned by institutional investors. 28.5% of Propanc Biopharma shares are owned by insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Akari Therapeutics beats Propanc Biopharma on 10 of the 11 factors compared between the two stocks.

How does Propanc Biopharma compare to Exicure?

Exicure (NASDAQ:XCUR) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Exicure is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	N/A	N/A	-$4.95M	-$1.55	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

In the previous week, Propanc Biopharma had 1 more articles in the media than Exicure. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for Exicure. Exicure's average media sentiment score of 0.43 beat Propanc Biopharma's score of 0.30 indicating that Exicure is being referred to more favorably in the media.

Company	Overall Sentiment
Exicure	Neutral
Propanc Biopharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exicure has a beta of 3.61, suggesting that its share price is 261% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.49, suggesting that its share price is 249% more volatile than the broader market.

42.8% of Exicure shares are owned by institutional investors. 52.8% of Exicure shares are owned by company insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Propanc Biopharma's return on equity of -151.28% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
Propanc Biopharma	N/A	-151.28%	-109.53%

Summary

Exicure beats Propanc Biopharma on 7 of the 10 factors compared between the two stocks.

Get Propanc Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPCB vs. The Competition

Export

Metric	Propanc Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.30M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.06	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.08	89.45
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.05	7.88	10.28	6.07
Net Income	-$58.92M	$23.86M	$3.60B	$331.99M
7 Day Performance	-8.05%	-3.82%	-1.27%	-0.63%
1 Month Performance	-9.27%	-2.61%	-0.37%	-2.00%
1 Year Performance	-99.07%	32.79%	18.30%	13.62%

Propanc Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPCB Propanc Biopharma	0.4693 of 5 stars	$1.37 -5.5%	N/A	-98.8%	$3.30M	N/A	N/A	1	Short Interest Increase
PHIO Phio Pharmaceuticals	4.0089 of 5 stars	$1.08 +4.9%	$14.00 +1,196.3%	-58.6%	$12.55M	N/A	N/A	10
INAB IN8bio	3.9762 of 5 stars	$1.26 -5.3%	$4.00 +217.5%	-50.2%	$12.41M	N/A	N/A	20	Short Interest Decrease
BLRX BioLineRx	0.318 of 5 stars	$2.83 -2.4%	N/A	-37.5%	$12.37M	$1.18M	N/A	40
AKTX Akari Therapeutics	3.305 of 5 stars	$10.66 -3.2%	$32.33 +203.3%	-80.2%	$12.21M	N/A	N/A	9	News Coverage Analyst Downgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPCB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Propanc Biopharma (PPCB) Competitors

PPCB vs. PHIO, INAB, BLRX, AKTX, and XCUR

How does Propanc Biopharma compare to Phio Pharmaceuticals?

Summary

How does Propanc Biopharma compare to IN8bio?

Summary

How does Propanc Biopharma compare to BioLineRx?

Summary

How does Propanc Biopharma compare to Akari Therapeutics?

Summary

How does Propanc Biopharma compare to Exicure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Propanc Biopharma (PPCB) Competitors

PPCB vs. PHIO, INAB, BLRX, AKTX, and XCUR

How does Propanc Biopharma compare to Phio Pharmaceuticals?

Which has more risk and volatility, PHIO or PPCB?

Which has preferable earnings & valuation, PHIO or PPCB?

Do analysts rate PHIO or PPCB?

Does the media favor PHIO or PPCB?

Do insiders & institutionals have more ownership in PHIO or PPCB?

Is PHIO or PPCB more profitable?

Summary

How does Propanc Biopharma compare to IN8bio?

Is PPCB or INAB more profitable?

Which has more volatility and risk, PPCB or INAB?

Do insiders and institutionals hold more shares of PPCB or INAB?

Which has better valuation & earnings, PPCB or INAB?

Do analysts recommend PPCB or INAB?

Does the media favor PPCB or INAB?

Summary

How does Propanc Biopharma compare to BioLineRx?

Do institutionals and insiders hold more shares of PPCB or BLRX?

Is PPCB or BLRX more profitable?

Which has more risk & volatility, PPCB or BLRX?

Does the media prefer PPCB or BLRX?

Which has higher valuation & earnings, PPCB or BLRX?

Do analysts rate PPCB or BLRX?

Summary

How does Propanc Biopharma compare to Akari Therapeutics?

Which has more volatility and risk, PPCB or AKTX?

Do analysts rate PPCB or AKTX?

Is PPCB or AKTX more profitable?

Which has preferable valuation and earnings, PPCB or AKTX?

Does the media refer more to PPCB or AKTX?

Do insiders & institutionals have more ownership in PPCB or AKTX?

Summary

How does Propanc Biopharma compare to Exicure?

Which has stronger valuation and earnings, XCUR or PPCB?

Does the media favor XCUR or PPCB?

Do analysts recommend XCUR or PPCB?

Which has more volatility and risk, XCUR or PPCB?

Do institutionals and insiders hold more shares of XCUR or PPCB?

Is XCUR or PPCB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPCB vs. The Competition

Propanc Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools